Literature DB >> 28049034

Hypervascular Lesions of the Cerebellopontine Angle: The Relevance of Angiography as a Diagnostic and Therapeutic Tool and the Role of Stereotactic Radiosurgery in Management. A Comprehensive Review.

Yosef Laviv1, Ajith Thomas2, Ekkehard M Kasper2.   

Abstract

BACKGROUND: The cerebellopontine angle (CPA) is a narrowed skull base area containing important cranial nerves and vessels and bordering with eloquent areas of the posterior fossa. Tumors of the CPA are a heterogeneous group and can have extradural, intradural/extra-axial, or intra-axial origins. Their vascular supply changes depending on their anatomic origin. Symptomatic, large CPA tumors require surgical resection in order to prevent irreversible, severe neurological damages. However, its tight and strategical location make surgery in the CPA very challenging and require appropriate pre-surgical planning. Pre-surgical diagnosis is of great importance as it allows us to choose the optimal management for the particular patient. This is of further significance when encountering high-risk lesions such as hypervascular tumors. Neurosurgeons should utilize every available pre-surgical diagnostic modalities as well as neo-adjuvant treatments in order to reduce such risks.
METHODS: We review all reported cases of hypervascular lesions of the CPA and discuss the roles of angiography and stereotactic radiosurgery in their management.
RESULTS: Three lesions of the CPA can be considered as truly hypervascular: hemangioblastomas, hemangiopericytomas and paragangliomas. All lesions share many radiological features. However, each lesion has a different anatomical origin and hence, has a characteristic vascular supply. Pre-surgical angiography can be utilized as a diagnostic tool to narrow down the differential diagnosis of a vascular CPA lesion, based on the predominant supplying vessel. In addition, pre-surgical embolization at time of angiography will narrow the associated surgical risks.
CONCLUSIONS: Angiography is a crucial diagnostic and therapeutic tool, helping both in narrowing the presurgical differential diagnosis and in controlling intraoperative bleeding. Because of the high surgical risks associated with resection of vascular tumors in the CPA, noninvasive treatments, such as stereotactic radiosurgery, also may have a crucial role.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiography; Cerebellopontine angle; Hemangioblastoma; Hemangiopericytoma; Paraganglioma

Mesh:

Year:  2016        PMID: 28049034     DOI: 10.1016/j.wneu.2016.12.091

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Unusual case of hemangioblastoma of the cerebellopontine angle.

Authors:  A R Persad; Y H Khormi; F van Landeghem; M M Chow
Journal:  Surg Neurol Int       Date:  2017-11-01

2.  Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife.

Authors:  Lichao Huang; Jingmin Bai; Yanyang Zhang; Zhiqiang Cui; Zhizhong Zhang; Jiwei Li; Jinyuan Wang; Xinguang Yu; Zhipei Ling; Baolin Qu; Longsheng Pan
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

3.  Hemangioblastoma of the Cerebellopontine Angle Evaluated with Pseudocontinuous Arterial Spin Labeling.

Authors:  Seiya Kishi; Masayuki Maeda; Ryota Kogue; Maki Umino; Toshio Matsubara; Hajime Sakuma
Journal:  Magn Reson Med Sci       Date:  2020-03-04       Impact factor: 2.471

4.  Successful preoperative embolization of a cystic-solid variant of cerebellopontine angle hemangioblastoma.

Authors:  Badr Boutakioute; Yosra Zouine; Anass Chehboun; Meriem Ouali; Najat Cherif Idrissi El Ganouni
Journal:  Radiol Case Rep       Date:  2022-10-05

5.  Diagnostic challenges of posterior fossa hemangioblastomas: Refining current radiological classification scheme.

Authors:  Eui Hyun Kim; Ju Hyung Moon; Seok-Gu Kang; Kyu Sung Lee; Jong Hee Chang
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.